Hsp90: A new player in DNA Repair?

Biomolecules

Volumn 5, Issue 4, 2015, Pages 2589-2618

  Pennisi, Rosa ^a   Ascenzi, Paolo ^a,b   di Masi, Alessandra ^a,b  

^a ROMA TRE UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Base excision repair; DNA damage response; DNA double strand break; DNA repair; Hsp90; Hsp90 inhibitors; Mismatch repair; Translation synthesis

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHAPERONE; CHECKPOINT KINASE 1; DNA DEPENDENT PROTEIN KINASE; GEFITINIB; HEAT SHOCK PROTEIN 90; HISTONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN MSH2; RAD51 PROTEIN; XRCC1 PROTEIN;

APOPTOSIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; FANCONI ANEMIA; HUMAN; MISMATCH REPAIR; NEOPLASM; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; DNA DAMAGE; GENETICS; METABOLISM; PHYSIOLOGY;

DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; HSP90 HEAT-SHOCK PROTEINS; HUMANS;

EID: 85012040933     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5042589     Document Type: Review

References (201)

1. Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. Adapting proteostasis for disease intervention. Science 2008, 319, 916-919.
2. Taipale, M.; Jarosz, D.F.; Lindquist, S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 2010, 11, 515-528.
3. Makhnevych, T.; Houry, W.A. The role of Hsp90 in protein complex assembly. Biochim. Biophys. Acta 2012, 1823, 674-682.
4. Neckers, L. Heat shock protein 90: The cancer chaperone. J. Biosci. 2007, 32, 517-530.
5. Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10, 537-549.
6. Wandinger, S.K.; Richter, K.; Buchner, J. The Hsp90 chaperone machinery. J. Biol. Chem. 2008, 283, 18473-18477.
7. Zhao, R.; Davey, M.; Hsu, Y.C.; Kaplanek, P.; Tong, A.; Parsons, A.B.; Krogan, N.; Cagney, G.; Mai, D.; Greenblatt, J.; et al. Navigating the chaperone network: An integrative map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell 2005, 120, 715-727.
8. Csermely, P.; Schnaider, T.; Soti, C.; Prohaszka, Z.; Nardai, G. The 90-kDa molecular chaperone family: Structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 1998, 79, 129-168.
9. Sreedhar, A.S.; Kalmar, E.; Csermely, P.; Shen, Y.F. Hsp90 isoforms: Functions, expression and clinical importance. FEBS Lett. 2004, 562, 11-15.
10. Echtenkamp, F.J.; Freeman, B.C. Expanding the cellular molecular chaperone network through the ubiquitous cochaperones. Biochim. Biophys. Acta 2012, 1823, 668-673.
11. Quadroni, M.; Potts, A.; Waridel, P. Hsp90 inhibition induces both protein-specific and global changes in the ubiquitinome. J. Proteom. 2015, 29, 120-215.
12. Young, J.C.; Moarefi, I.; Hartl, F.U. Hsp90: A specialized but essential protein-folding tool. J. Cell Biol. 2001, 154, 267-273.
13. Catlett, M.G.; Kaplan, K.B. Sgt1p is a unique co-chaperone that acts as a client adaptor to link Hsp90 to Skp1p. J. Biol. Chem. 2006, 281, 33739-33748.
14. Kimura, Y.; Rutherford, S.L.; Miyata, Y.; Yahara, I.; Freeman, B.C.; Yue, L.; Morimoto, R.I.; Lindquist, S. Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev. 1997, 11, 1775-1785.
15. Echtenkamp, F.J.; Zelin, E.; Oxelmark, E.; Woo, J.I.; Andrews, B.J.; Garabedian, M.; Freeman, B.C. Global functional map of the p23 molecular chaperone reveals an extensive cellular network. Mol. Cell 2011, 43, 229-241.
16. Soroka, J.; Wandinger, S.K.; Mausbacher, N.; Schreiber, T.; Richter, K.; Daub, H.; Buchner, J. Conformational switching of the molecular chaperone Hsp90 via regulated phosphorylation. Mol. Cell 2012, 45, 517-528.
17. Pratt, W.B.; Dittmar, K.D. Studies with Purified Chaperones Advance the Understanding of the Mechanism of Glucocorticoid Receptor-hsp90 Heterocomplex Assembly. Trends Endocrinol. Metab. 1998, 9, 244-252.
18. Workman, P. Altered states: Selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 2004, 10, 47-51.
19. Iannotti, A.M.; Rabideau, D.A.; Dougherty, J.J. Characterization of purified avian 90,000-Da heat shock protein. Arch. Biochem. Biophys. 1988, 264, 54-60.
20. Lees-Miller, S.P.; Anderson, C.W. The human double-stranded DNA-activated protein kinase phosphorylates the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal threonine residues. J. Biol. Chem. 1989, 264, 17275-17280.
21. Welch, W.J.; Feramisco, J.R. Purification of the major mammalian heat shock proteins. J. Biol. Chem. 1982, 257, 14949-14959.
22. Welch, W.J. The role of heat-shock proteins as molecular chaperones. Curr. Opin. Cell Biol. 1991, 3, 1033-1038.
23. Jhaveri, K.; Ochiana, S.O.; Dunphy, M.P.; Gerecitano, J.F.; Corben, A.D.; Peter, R.I.; Janjigian, Y.Y.; Gomes-DaGama, E.M.; Koren, J.; III; Modi, S.; et al. Heat shock protein 90 inhibitors in the treatment of cancer: Current status and future directions. Expert. Opin. Investig. Drugs 2014, 23, 611-628.
24. Proia, D.A.; Kaufmann, G.F. Targeting heat-shock protein 90 (Hsp90) as a complementary strategy to immune checkpoint blockade for cancer therapy. Cancer Immunol. Res. 2015, 3, 583-589.
25. Bhat, R.; Tummalapalli, S.R.; Rotella, D.P. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. J. Med. Chem. 2014, 57, 8718-8728.
26. Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 2012, 1823, 742-755.
27. Hahn, J.S. The Hsp90 chaperone machinery: From structure to drug development. BMB. Rep. 2009, 42, 623-630.
28. Hong, D.S.; Banerji, U.; Tavana, B.; George, G.C.; Aaron, J.; Kurzrock, R. Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treat. Rev. 2013, 39, 375-387.
29. Li, J.; Buchner, J. Structure, function and regulation of the Hsp90 machinery. Biomed. J. 2013, 36, 106-117.
30. Lianos, G.D.; Alexiou, G.A.; Mangano, A.; Mangano, A.; Rausei, S.; Boni, L.; Dionigi, G.; Roukos, D.H. The role of heat shock proteins in cancer. Cancer Lett. 2015, 360, 114-118.
31. Luo, W.; Rodina, A.; Chiosis, G. Heat shock protein 90: Translation from cancer to Alzheimer's disease treatment? BMC Neurosci. 2008, 9, doi:10.1186/1471-2202-9-S2-S7.
32. Paul, S.; Mahanta, S. Association of heat-shock proteins in various neurodegenerative disorders: Is it a master key to open the therapeutic door? Mol. Cell. Biochem. 2014, 386, 45-61.
33. Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.
34. Yeyati, P.L.; van Heyningen, V. Incapacitating the evolutionary capacitor: Hsp90 modulation of disease. Curr. Opin. Genet. Dev. 2008, 18, 264-272.
35. Camphausen, K.; Tofilon, P.J. Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin. Cancer Res. 2007, 13, 4326-4330.
36. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M.F.; Fritz, L.C.; Burrows, F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
37. Kirschke, E.; Goswami, D.; Southworth, D.; Griffin, P.R.; Agard, D.A. Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles. Cell 2014, 157, 1685-1697.
38. Neckers, L.; Ivy, S.P. Heat shock protein 90. Curr. Opin. Oncol. 2003, 15, 419-424.
39. Sangster, T.A.; Lindquist, S.; Queitsch, C. Under cover: Causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays 2004, 26, 348-362.
40. Segnitz, B.; Gehring, U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J. Biol. Chem. 1997, 272, 18694-18701.
41. Sharp, S.; Workman, P. Inhibitors of the HSP90 molecular chaperone: Current status. Adv. Cancer Res. 2006, 95, 323-348.
42. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 2012, 18, 64-76.
43. Chiosis, G.; Neckers, L. Tumor selectivity of Hsp90 inhibitors: The explanation remains elusive. ACS Chem. Biol. 2006, 1, 279-284.
44. Ferrarini, M.; Heltai, S.; Zocchi, M.R.; Rugarli, C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer 1992, 51, 613-619.
45. Calderwood, S.K.; Khaleque, M.A.; Sawyer, D.B.; Ciocca, D.R. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem. Sci. 2006, 31, 164-172.
46. Chiosis, G.; Vilenchik, M.; Kim, J.; Solit, D. Hsp90: The vulnerable chaperone. Drug Discov. Today 2004, 9, 881-888.
47. Fionda, C.; Soriani, A.; Malgarini, G.; Iannitto, M.L.; Santoni, A.; Cippitelli, M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J. Immunol. 2009, 183, 4385-4394.
48. Alexiou, G.A.; Vartholomatos, G.; Stefanaki, K.; Patereli, A.; Dova, L.; Karamoutsios, A.; Lallas, G.; Sfakianos, G.; Moschovi, M.; Prodromou, N. Expression of heat shock proteins in medulloblastoma. J. Neurosurg. Pediatr. 2013, 12, 452-457.
49. Zagouri, F.; Sergentanis, T.N.; Nonni, A.; Papadimitriou, C.A.; Michalopoulos, N.V.; Domeyer, P.; Theodoropoulos, G.; Lazaris, A.; Patsouris, E.; Zogafos, E.; et al. Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions. BMC Cancer 2010, doi:10.1186/1471-2407-10-353.
50. Nagaraju, G.P.; Long, T.E.; Park, W.; Landry, J.C.; Taliaferro-Smith, L.; Farris, A.B.; Diaz, R.; El Rayes, B.F. Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer. Mol. Carcinog. 2014, doi:10.1002/mc.22185.
51. Annamalai, B.; Liu, X.; Gopal, U.; Isaacs, J.S. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: Implications for cancer cell migration and metastasis. Mol. Cancer Res. 2009, 7, 1021-1032.
52. Kawabe, M.; Mandic, M.; Taylor, J.L.; Vasquez, C.A.; Wesa, A.K.; Neckers, L.M.; Storkus, W.J. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Res. 2009, 69, 6995-7003.
53. Bisht, K.S.; Bradbury, C.M.; Mattson, D.; Kaushal, A.; Sowers, A.; Markovina, S.; Ortiz, K.L.; Sieck, L.K.; Isaacs, J.S.; Brechbiel, M.W.; et al. Geldanamycin and 17-allylamino-17- demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 2003, 63, 8984-8995.
54. Bull, E.E.; Dote, H.; Brady, K.J.; Burgan, W.E.; Carter, D.J.; Cerra, M.A.; Oswald, K.A.; Hollingshead, M.G.; Camphausen, K.; Tofilon, P.J. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin. Clin. Cancer Res. 2004, 10, 8077-8084.
55. Hirakawa, Y.; Suzuki, S.; Archibald, J.M.; Keeling, P.J.; Ishida, K. Overexpression of molecular chaperone genes in nucleomorph genomes. Mol. Biol. Evol. 2014, 31, 1437-1443.
56. Koll, T.T.; Feis, S.S.; Wright, M.H.; Teniola, M.M.; Richardson, M.M.; Robles, A.I.; Bradsher, J.; Capala, J.; Varticovski, L. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol. Cancer Ther. 2008, 7, 1985-1992.
57. Noguchi, M.; Yu, D.; Hirayama, R.; Ninomiya, Y.; Sekine, E.; Kubota, N.; Ando, K.; Okayasu, R. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem. Biophys. Res. Commun. 2006, 351, 658-663.
58. Russell, J.S.; Burgan, W.; Oswald, K.A.; Camphausen, K.; Tofilon, P.J. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: A multitarget approach to radiosensitization. Clin. Cancer Res. 2003, 9, 3749-3755.
59. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad. Sci. 2007, 1113, 202-216.
60. Dote, H.; Burgan, W.E.; Camphausen, K.; Tofilon, P.J. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res. 2006, 66, 9211-9220.
61. Han, F.F.; Li, L.; Shang, B.Y.; Shao, R.G.; Zhen, Y.S. Hsp90 inhibitor geldanamycin enhances the antitumor efficacy of enediyne lidamycin in association with reduced DNA damage repair. Asian Pac. J. Cancer Prev. 2014, 15, 7043-7048.
62. Ri, M.; Iida, S.; Nakashima, T.; Miyazaki, H.; Mori, F.; Ito, A.; Inagaki, A.; Kusumoto, S.; Ishida, T.; Komatsu, H.; et al. Bortezomib-resistant myeloma cell lines: a Role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010, 24, 1506-1512.
63. Robles, A.I.; Wright, M.H.; Gandhi, B.; Feis, S.S.; Hanigan, C.L.; Wiestner, A.; Varticovski, L. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin. Cancer Res. 2006, 12, 6547-6556.
64. Dehner, A.; Furrer, J.; Richter, K.; Schuster, I.; Buchner, J.; Kessler, H. NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol. Chembiochem 2003, 4, 870-877.
65. Roe, S.M.; Prodromou, C.; O'Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42, 260-266.
66. Seo, Y.H. Small Molecule Inhibitors to Disrupt Protein-protein Interactions of Heat Shock Protein 90 Chaperone Machinery. J. Cancer Prev. 2015, 20, 5-11.
67. Stebbins, C.E.; Russo, A.A.; Schneider, C.; Rosen, N.; Hartl, F.U.; Pavletich, N.P. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
68. Jackson, S.E. Hsp90: Structure and function. Top. Curr. Chem. 2013, 328, 155-240.
69. Supko, J.G.; Hickman, R.L.; Grever, M.R.; Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36, 305-315.
70. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 4152-4161.
71. Ronnen, E.A.; Kondagunta, G.V.; Ishill, N.; Sweeney, S.M.; Deluca, J.K.; Schwartz, L.; Bacik, J.; Motzer, R.J. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investig. New Drugs 2006, 24, 543-546.
72. Smith, V.; Sausville, E.A.; Camalier, R.F.; Fiebig, H.H.; Burger, A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17- demethoxygeldanamycin (17AAG) in vitro: Effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 2005, 56, 126-137.
73. Heath, E.I.; Gaskins, M.; Pitot, H.C.; Pili, R.; Tan, W.; Marschke, R.; Liu, G.; Hillman, D.; Sarkar, F.; Sheng, S.; et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Prostate Cancer 2005, 4, 138-141.
74. Richardson, P.G.; Badros, A.Z.; Jagannath, S.; Tarantolo, S.; Wolf, J.L.; Albitar, M.; Berman, D.; Messina, M.; Anderson, K.C. Tanespimycin with bortezomib: Activity in relapsed/refractory patients with multiple myeloma. Br. J. Haematol. 2010, 150, 428-437.
75. Pacey, S.; Gore, M.; Chao, D.; Banerji, U.; Larkin, J.; Sarker, S.; Owen, K.; Asad, Y.; Raynaud, F.; Walton, M.; Judson, I.; Workman, P.; Eisen, T. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investig. New Drugs 2012, 30, 341-349.
76. Oki, Y.; Copeland, A.; Romaguera, J.; Fayad, L.; Fanale, M.; Faria, S.C.; Medeiros, L.J.; Ivy, P.; Younes, A. Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk. Lymphoma 2012, 53, 990-992.
77. Kitson, R.R.; Chang, C.H.; Xiong, R.; Williams, H.E.; Davis, A.L.; Lewis, W.; Dehn, D.L.; Siegel, D.; Roe, S.M.; Prodromou, C.; et al. Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat. Chem. 2013, 5, 307-314.
78. Zhang, J.; Zheng, Z.; Zhao, Y.; Zhang, T.; Gu, X.; Yang, W. The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells. Clin. Exp. Med. 2013, 13, 323-328.
79. Hollingshead, M.; Alley, M.; Burger, A.M.; Borgel, S.; Pacula-Cox, C.; Fiebig, H.H.; Sausville, E.A. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol. 2005, 56, 115-125.
80. Onuoha, S.C.; Mukund, S.R.; Coulstock, E.T.; Sengerova, B.; Shaw, J.; McLaughlin, S.H.; Jackson, S.E. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J. Mol. Biol. 2007, 372, 287-297.
81. Pacey, S.; Wilson, R.H.; Walton, M.; Eatock, M.M.; Hardcastle, A.; Zetterlund, A.; Arkenau, H.T.; Moreno-Farre, J.; Banerji, U.; Roels, B.; et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 2011, 17, 1561-1570.
82. He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; She, Y.; Wu, N.; Immormino, R.M.; Gewirth, D.T.; Chiosis, G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 2006, 49, 381-390.
83. Usmani, S.Z.; Bona, R.D.; Chiosis, G.; Li, Z. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J. Hematol. Oncol. 2010, 3, doi:10.1186/1756-8722-3-40.
84. Ambati, S.R.; Lopes, E.C.; Kosugi, K.; Mony, U.; Zehir, A.; Shah, S.K.; Taldone, T.; Moreira, A.L.; Meyers, P.A.; Chiosis, G.; et al. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Mol. Oncol. 2014, 8, 323-336.
85. Brough, P.A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J.E.; Cheung, K M.; Collins, I.; Davies, N.G.; Drysdale, M.J.; et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51, 196-218.
86. Eccles, S.A.; Massey, A.; Raynaud, F.I.; Sharp, S.Y.; Box, G.; Valenti, M.; Patterson, L.; de Haven Brandon, A.; Gowan, S.; Boxall, F.; et al. NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68, 2850-2860.
87. Ueno, T.; Tsukuda, K.; Toyooka, S.; Ando, M.; Takaoka, M.; Soh, J.; Asano, H.; Maki, Y.; Muraoka, T.; Tanaka, N.; et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer 2012, 76, 26-31.
88. Ying, W.; Du, Z.; Sun, L.; Foley, K.P.; Proia, D.A.; Blackman, R.K.; Zhou, D.; Inoue, T.; Tatsuta, N.; Sang, J.; et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 2012, 11, 475-484.
89. Gomez-Casal, R.; Bhattacharya, C.; Epperly, M.W.; Basse, P.H.; Wang, H.; Wang, X.; Proia, D.A.; Greenberger, J.S.; Socinski, M.A.; Levina, V. The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells. Cancers 2015, 7, 876-907.
90. He, S.; Smith, D.L.; Sequeira, M.; Sang, J.; Bates, R.C.; Proia, D.A. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Investig. New Drugs. 2014, 32, 577-586.
91. Proia, D.A.; Bates, R.C. Ganetespib and HSP90: Translating preclinical hypotheses into clinical promise. Cancer. Res. 2014, 74, 1294-1300.
92. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera: A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-1612.
93. Shiau, A.K.; Harris, S.F.; Southworth, D.R.; Agard, D.A. Structural analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006, 127, 329-340.
94. Ali, M.M.; Roe, S.M.; Vaughan, C.K.; Meyer, P.; Panaretou, B.; Piper, P.W.; Prodromou, C.; Pearl, L.H. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440, 1013-1017.
95. Bridge, G.; Rashid, S.; Martin, S.A. DNA mismatch repair and oxidative DNA damage: Implications for cancer biology and treatment. Cancers 2014, 6, 1597-1614.
96. Chistiakov, D.A.; Voronova, N.V.; Chistiakov, P.A. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol. 2008, 47, 809-824.
97. Hoeijmakers, J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411, 366-374.
98. Dezwaan, D.C.; Freeman, B.C. HSP90: The rosetta stone for cellular protein dynamics? Cell Cycle 2008, 7, 1006-1012.
99. Quanz, M.; Herbette, A.; Sayarath, M.; de Koning, L.; Dubois, T.; Sun, J.S.; Dutreix, M. Heat shock protein 90α (Hsp90α) is phosphorylated in response to DNA damage and accumulates in repair foci. J. Biol. Chem. 2012, 287, 8803-8815.
100. Solier, S.; Kohn, K.W.; Scroggins, B.; Xu, W.; Trepel, J.; Neckers, L.; Pommier, Y. Heat shock protein 90alpha (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic response. Proc. Natl. Acad. Sci. USA 2012, 109, 12866-12872.
101. Kumar, R.; Horikoshi, N.; Singh, M.; Gupta, A.; Misra, H.S.; Albuquerque, K.; Hunt, C.R.; Pandita, T.K. Chromatin modifications and the DNA damage response to ionizing radiation. Front. Oncol. 2012, 2, doi:10.3389/fonc.2012.00214.
102. Bassing, C.H.; Suh, H.; Ferguson, D.O.; Chua, K.F.; Manis, J.; Eckersdorff, M.; Gleason, M.; Bronson, R.; Lee, C.; Alt, F.W. Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003, 114, 359-370.
103. Scully, R.; Xie, A. Double strand break repair functions of histone H2AX. Mutat. Res. 2013, 750, 5-14.
104. Kanaar, R.; Hoeijmakers, J.H.; van Gent, D.C. Molecular mechanisms of DNA double strand break repair. Trends Cell Biol. 1998, 8, 483-489.
105. Lieber, M.R.; Ma, Y.; Pannicke, U.; Schwarz, K. Mechanism and regulation of human non-homologous DNA end-joining. Nat. Rev. Mol. Cell Biol. 2003, 4, 712-720.
106. O'Driscoll, M.; Jeggo, P.A. The role of double-strand break repair-Insights from human genetics. Nat. Rev. Genet. 2006, 7, 45-54.
107. Van Gent, D.C.; Hoeijmakers, J.H.; Kanaar, R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2001, 2, 196-206.
108. Lemaitre, C.; Soutoglou, E. Double strand break (DSB) repair in heterochromatin and heterochromatin proteins in DSB repair. DNA Repair 2014, 19, 163-168.
109. Pierce, A.J.; Jasin, M. NHEJ deficiency and disease. Mol. Cell 2001, 8, 1160-1161.
110. Rothkamm, K.; Kruger, I.; Thompson, L.H.; Lobrich, M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol. Cell. Biol. 2003, 23, 5706-5715.
111. Chapman, J.R.; Taylor, M.R.; Boulton, S.J. Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell 2012, 47, 497-510.
112. Lieber, M.R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 2010, 79, 181-211.
113. Goodarzi, A.A.; Jeggo, P.A. The repair and signaling responses to DNA double-strand breaks. Adv. Genet. 2013, 82, 1-45.
114. Dynan, W.S.; Yoo, S. Interaction of Ku protein and DNA-dependent protein kinase catalytic subunit with nucleic acids. Nucleic Acids Res. 1998, 26, 1551-1559.
115. Ma, Y.; Pannicke, U.; Schwarz, K.; Lieber, M.R. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002, 108, 781-794.
116. Gupta, A.; Hunt, C.R.; Chakraborty, S.; Pandita, R.K.; Yordy, J.; Ramnarain, D.B.; Horikoshi, N.; Pandita, T.K. Role of 53BP1 in the regulation of DNA double-strand break repair pathway choice. Radiat. Res. 2014, 181, 1-8.
117. Nimonkar, A.V.; Genschel, J.; Kinoshita, E.; Polaczek, P.; Campbell, J.L.; Wyman, C.; Modrich, P.; Kowalczykowski, S.C. BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev. 2011, 25, 350-362.
118. Di Masi, A.; Gullotta, F.; Cappadonna, V.; Leboffe, L.; Ascenzi, P. Cancer predisposing mutations in BRCT domains. IUBMB Life 2011, 63, 503-512.
119. Arlander, S.J.; Eapen, A.K.; Vroman, B.T.; McDonald, R.J.; Toft, D.O.; Karnitz, L.M. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J. Biol. Chem. 2003, 278, 52572-52577.
120. Fang, Q.; Inanc, B.; Schamus, S.; Wang, X.H.; Wei, L.; Brown, A.R.; Svilar, D.; Sugrue, K.F.; Goellner, E.M.; Zeng, X.; et al. HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase beta. Nat. Commun. 2014, 5, doi:10.1038/ncomms6513.
121. Furuta, T.; Takemura, H.; Liao, Z.Y.; Aune, G.J.; Redon, C.; Sedelnikova, O.A.; Pilch, D.R.; Rogakou, E.P.; Celeste, A.; Chen, H.T.; et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 2003, 278, 20303-20312.
122. Schnaider, T.; Oikarinen, J.; Ishiwatari-Hayasaka, H.; Yahara, I.; Csermely, P. Interactions of Hsp90 with histones and related peptides. Life Sci. 1999, 65, 2417-2426.
123. Smogorzewska, A.; Matsuoka, S.; Vinciguerra, P.; McDonald, E.R., III; Hurov, K.E.; Luo, J.; Ballif, B.A.; Gygi, S.P.; Hofmann, K.; D'Andrea, A.D.; et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007, 129, 289-301.
124. Stecklein, S.R.; Kumaraswamy, E.; Behbod, F.; Wang, W.; Chaguturu, V.; Harlan-Williams, L.M.; Jensen, R.A. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc. Natl. Acad. Sci. USA 2012, 109, 13650-13655.
125. Wang, H.; Zhang, X.; Wang, P.; Yu, X.; Essers, J.; Chen, D.; Kanaar, R.; Takeda, S.; Wang, Y. Characteristics of DNA-binding proteins determine the biological sensitivity to high-linear energy transfer radiation. Nucleic Acids Res. 2010, 38, 3245-3251.
126. Whitesell, L.; Mimnaugh, E.G.; de Costa, B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8328.
127. Li, Y.; Zhang, T.; Schwartz, S.J.; Sun, D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential. Drug Resist. Updat. 2009, 12, 17-27.
128. Pacey, S.; Banerji, U.; Judson, I.; Workman, P. Hsp90 inhibitors in the clinic. Handb. Exp. Pharmacol. 2006, 331-358.
129. Chiosis, G. Targeting chaperones in transformed systems-A focus on Hsp90 and cancer. Expert. Opin. Ther. Targets 2006, 10, 37-50.
130. Solit, D.B.; Chiosis, G. Development and application of Hsp90 inhibitors. Drug Discov. Today 2008, 13, 38-43.
131. Cheung, K.M.; Matthews, T.P.; James, K.; Rowlands, M.G.; Boxall, K.J.; Sharp, S.Y.; Maloney, A.; Roe, S.M.; Prodromou, C.; Pearl, L.H.; et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 3338-3343.
132. McDonald, E.; Jones, K.; Brough, P.A.; Drysdale, M.J.; Workman, P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 2006, 6, 1193-1203.
133. Johnson, J.L. Evolution and function of diverse Hsp90 homologs and cochaperone proteins. Biochim. Biophys. Acta 2012, 1823, 607-613.
134. Ernst, A.; Anders, H.; Kapfhammer, H.; Orth, M.; Hennel, R.; Seidl, K.; Winssinger, N.; Belka, C.; Unkel, S.; Lauber, K. HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. Cancer Lett. 2015, 365, 211-222.
135. Falsone, S.F.; Gesslbauer, B.; Tirk, F.; Piccinini, A.M.; Kungl, A.J. A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Lett. 2005, 579, 6350-6354.
136. Zaidi, S.; McLaughlin, M.; Bhide, S.A.; Eccles, S.A.; Workman, P.; Nutting, C.M.; Huddart, R.A.; Harrington, K.J. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS ONE 2012, 7, e35436.
137. Parameswaran, B.; Chiang, H.C.; Lu, Y.; Coates, J.; Deng, C.X.; Baer, R.; Lin, H.K.; Li, R.; Paull, T.T.; Hu, Y. Damage-induced BRCA1 phosphorylation by Chk2 contributes to the timing of end resection. Cell Cycle 2015, 14, 437-448.
138. Cortez, D.; Wang, Y.; Qin, J.; Elledge, S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999, 286, 1162-1166.
139. Yarden, R.I.; Pardo-Reoyo, S.; Sgagias, M.; Cowan, K.H.; Brody, L.C. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet. 2002, 30, 285-289.
140. Bhattacharyya, A.; Ear, U.S.; Koller, B.H.; Weichselbaum, R.R.; Bishop, D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 2000, 275, 23899-23903.
141. Chen, L.; Nievera, C.J.; Lee, A.Y.; Wu, X. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J. Biol. Chem. 2008, 283, 7713-7720.
142. D'Andrea, A.D.; Grompe, M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 2003, 3, 23-34.
143. Zhong, Q.; Chen, C.F.; Li, S.; Chen, Y.; Wang, C.C.; Xiao, J.; Chen, P.L.; Sharp, Z.D.; Lee, W.H. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999, 285, 747-750.
144. Scata, K.A.; El Deiry, W.S. p53, BRCA1 and breast Cancer chemoresistance. Adv. Exp. Med. Biol. 2007, 608, 70-86.
145. Davies, A.A.; Masson, J.Y.; McIlwraith, M.J.; Stasiak, A.Z.; Stasiak, A.; Venkitaraman, A.R.; West, S.C. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol. Cell 2001, 7, 273-282.
146. Segawa, T.; Fujii, Y.; Tanaka, A.; Bando, S.; Okayasu, R.; Ohnishi, K.; Kubota, N. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71. Int. J. Mol. Med. 2014, 33, 559-564.
147. Dungey, F.A.; Caldecott, K.W.; Chalmers, A.J. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol. Cancer Ther. 2009, 8, 2243-2254.
148. Yao, Q.; Weigel, B.; Kersey, J. Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin. Cancer Res. 2007, 13, 1591-1600.
149. Zhou, B.B.; Elledge, S.J. The DNA damage response: Putting checkpoints in perspective. Nature 2000, 408, 433-439.
150. Dai, Y.; Grant, S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 2010, 16, 376-383.
151. Oakley, G.G.; Patrick, S.M. Replication protein A: Directing traffic at the intersection of replication and repair. Fron. Biosci. 2010, 15, 883-900.
152. Gonzalez Besteiro, M.A.; Gottifredi, V. The fork and the kinase: A DNA replication tale from a CHK1 perspective. Mutat. Res. Rev. Mutat. Res. 2015, 763, 168-180.
153. Roos-Mattjus, P.; Hopkins, K.M.; Oestreich, A.J.; Vroman, B.T.; Johnson, K.L.; Naylor, S.; Lieberman, H.B.; Karnitz, L.M. Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling. J. Biol. Chem. 2003, 278, 24428-24437.
154. Zachos, G.; Rainey, M.D.; Gillespie, D.A. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J. 2003, 22, 713-723.
155. Dittmann, K.; Mayer, C.; Fehrenbacher, B.; Schaller, M.; Raju, U.; Milas, L.; Chen, D.J.; Kehlbach, R.; Rodemann, H.P. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 2005, 280, 31182-31189.
156. Bertrand, R.; Solary, E.; O'Connor, P.; Kohn, K.W.; Pommier, Y. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res. 1994, 211, 314-321.
157. Strasser, A.; Jost, P.J.; Nagata, S. The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30, 180-192.
158. Solier, S.; Pommier, Y. The apoptotic ring: A novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle 2009, 8, 1853-1859.
159. Solier, S.; Sordet, O.; Kohn, K.W.; Pommier, Y. Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol. Cell. Biol. 2009, 29, 68-82.
160. Vasilevskaya, I.A.; O'Dwyer, P.J. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem. Pharmacol. 2005, 70, 580-589.
161. Solier, S.; Pommier, Y. MDC1 cleavage by caspase-3: A novel mechanism for inactivating the DNA damage response during apoptosis. Cancer Res. 2011, 71, 906-913.
162. Nakanishi, K.; Yang, Y.G.; Pierce, A.J.; Taniguchi, T.; Digweed, M.; D'Andrea, A.D.; Wang, Z.Q.; Jasin, M. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc. Natl. Acad. Sci. USA 2005, 102, 1110-1115.
163. Yamamoto, K.; Ishiai, M.; Matsushita, N.; Arakawa, H.; Lamerdin, J.E.; Buerstedde, J.M.; Tanimoto, M.; Harada, M.; Thompson, L.H.; Takata, M. Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells. Mol. Cell. Biol. 2003, 23, 5421-5430.
164. Oda, T.; Hayano, T.; Miyaso, H.; Takahashi, N.; Yamashita, T. Hsp90 regulates the Fanconi anemia DNA damage response pathway. Blood 2007, 109, 5016-5026.
165. Yamashita, T.; Oda, T.; Sekimoto, T. Hsp90 and the Fanconi anemia pathway: A molecular link between protein quality control and the DNA damage response. Cell Cycle 2007, 6, 2232-2235.
166. Gospodinov, A.; Herceg, Z. Chromatin structure in double strand break repair. DNA Repair 2013, 12, 800-810.
167. Jeggo, P.A.; Downs, J.A. Roles of chromatin remodellers in DNA double strand break repair. Exp. Cell Res. 2014, 329, 69-77.
168. Csordas, A. On the biological role of histone acetylation. Biochem. J. 1990, 265, 23-38.
169. Hill, C.S.; Rimmer, J.M.; Green, B.N.; Finch, J.T.; Thomas, J.O. Histone-DNA interactions and their modulation by phosphorylation of -Ser-Pro-X-Lys/Arg- motifs. EMBO J. 1991, 10, 1939-1948.
170. Khadake, J.R.; Rao, M.R. Condensation of DNA and chromatin by an SPKK-containing octapeptide repeat motif present in the C-terminus of histone H1. Biochemistry 1997, 36, 1041-1051.
171. Tarkka, T.; Oikarinen, J.; Grundstrom, T. Nucleotide and calcium-induced conformational changes in histone H1. FEBS Lett. 1997, 406, 56-60.
172. Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006, 7, 335-346.
173. Mo, C.; Dai, Y.; Kang, N.; Cui, L.; He, W. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. J. Biol. Chem. 2012, 287, 19242-19254.
174. Tung, H.Y.; Plunkett, B.; Huang, S.K.; Zhou, Y. Murine mast cells secrete and respond to interleukin-33. J. Interferon Cytokine Res. 2014, 34, 141-147.
175. Curtin, N.J.; Harris, A.L.; Aherne, G.W. Mechanism of cell death following thymidylate synthase inhibition: 2 -deoxyuridine-5 -triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991, 51, 2346-2352.
176. Van der Wilt, C.L.; Kuiper, C.M.; Peters, G.J. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines. Oncol. Res. 1999, 11, 383-391.
177. White, I.N. Tamoxifen: Is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr. Drug Metab. 2003, 4, 223-239.
178. Olivo-Marston, S.E.; Mechanic, L.E.; Mollerup, S.; Bowman, E.D.; Remaley, A.T.; Forman, M.R.; Skaug, V.; Zheng, Y.L.; Haugen, A.; Harris, C.C. Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women. Carcinogenesis 2010, 31, 1778-1786.
179. Ko, J.C.; Chiu, H.C.; Syu, J.J.; Jian, Y.J.; Chen, C.Y.; Jian, Y.T.; Huang, Y.J.; Wo, T.Y.; Lin, Y.W. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells. Biochem. Pharmacol. 2014, 88, 119-127.
180. Ko, J.C.; Chiu, H.C.; Syu, J.J.; Chen, C.Y.; Jian, Y.T.; Huang, Y.J.; Wo, T.Y.; Jian, Y.J.; Chang, P.Y.; Wang, T.J.; Lin, Y.W. Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells. Biochem. Biophys. Res. Commun. 2015, 456, 506-512.
181. Friedberg, E.C.; Lehmann, A.R.; Fuchs, R.P. Trading places: How do DNA polymerases switch during translesion DNA synthesis? Mol. Cell 2005, 18, 499-505.
182. Lehmann, A.R.; Niimi, A.; Ogi, T.; Brown, S.; Sabbioneda, S.; Wing, J.F.; Kannouche, P.L.; Green, C.M. Translesion synthesis: Y-family polymerases and the polymerase switch. DNA Repair 2007, 6, 891-899.
183. Yang, W.; Woodgate, R. What a difference a decade makes: Insights into translesion DNA synthesis. Proc. Natl. Acad. Sci. USA 2007, 104, 15591-15598.
184. Masutani, C.; Kusumoto, R.; Iwai, S.; Hanaoka, F. Mechanisms of accurate translesion synthesis by human DNA polymerase eta. EMBO J. 2000, 19, 3100-3109.
185. McCulloch, S.D.; Kokoska, R.J.; Kunkel, T.A. Efficiency, fidelity and enzymatic switching during translesion DNA synthesis. Cell Cycle 2004, 3, 580-583.
186. Kannouche, P.L.; Wing, J.; Lehmann, A.R. Interaction of human DNA polymerase eta with monoubiquitinated PCNA: A possible mechanism for the polymerase switch in response to DNA damage. Mol. Cell 2004, 14, 491-500.
187. Watanabe, K.; Tateishi, S.; Kawasuji, M.; Tsurimoto, T.; Inoue, H.; Yamaizumi, M. Rad18 guides poleta to replication stalling sites through physical interaction and PCNA monoubiquitination. EMBO J. 2004, 23, 3886-3896.
188. Sekimoto, T.; Oda, T.; Pozo, F.M.; Murakumo, Y.; Masutani, C.; Hanaoka, F.; Yamashita, T. The molecular chaperone Hsp90 regulates accumulation of DNA polymerase eta at replication stalling sites in UV-irradiated cells. Mol. Cell 2010, 37, 79-89.
189. Wang, X.; Heuvelman, D.M.; Carroll, J.A.; Dufield, D.R.; Masferrer, J.L. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells. Cancer Investig. 2010, 28, 635-641.
190. Lindahl, T.; Prigent, C.; Barnes, D.E.; Lehmann, A.R.; Satoh, M.S.; Roberts, E.; Nash, R.A.; Robins, P.; Daly, G. DNA joining in mammalian cells. Cold Spring Harb. Symp. Quant. Biol. 1993, 58, 619-624.
191. Kim, Y.J.; Wilson, D.M., III. Overview of base excision repair biochemistry. Curr. Mol. Pharmacol. 2012, 5, 3-13.
192. Svilar, D.; Goellner, E.M.; Almeida, K.H.; Sobol, R.W. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid. Redox Signal. 2011, 14, 2491-2507.
193. Braithwaite, E.K.; Kedar, P.S.; Stumpo, D.J.; Bertocci, B.; Freedman, J.H.; Samson, L.D.; Wilson, S.H. DNA polymerases beta and lambda mediate overlapping and independent roles in base excision repair in mouse embryonic fibroblasts. PLoS ONE 2010, 5, e12229.
194. Caldecott, K.W. XRCC1 and DNA strand break repair. DNA Repair 2003, 2, 955-969.
195. Shim, H.J.; Yun, J.Y.; Hwang, J.E.; Bae, W.K.; Cho, S.H.; Lee, J.H.; Kim, H.N.; Shin, M.H.; Kweon, S.S.; Lee, J.H.; et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 2010, 101, 1247-1254.
196. Caldecott, K.W. Single-strand break repair and genetic disease. Nat. Rev. Genet. 2008, 9, 619-631.
197. Brem, R.; Hall, J. XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res. 2005, 33, 2512-2520.
198. Toulany, M.; Dittmann, K.; Fehrenbacher, B.; Schaller, M.; Baumann, M.; Rodemann, H.P. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair 2008, 7, 1746-1756.
199. Della-Maria, J.; Zhou, Y.; Tsai, M.S.; Kuhnlein, J.; Carney, J.P.; Paull, T.T.; Tomkinson, A.E. Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J. Biol. Chem. 2011, 286, 33845-33853.
200. Saribasak, H.; Maul, R.W.; Cao, Z.; McClure, R.L.; Yang, W.; McNeill, D.R.; Wilson, D.M., III; Gearhart, P.J. XRCC1 suppresses somatic hypermutation and promotes alternative nonhomologous end joining in Igh genes. J. Exp. Med. 2011, 208, 2209-2216.
201. Tung, C.L.; Jian, Y.J.; Syu, J.J.; Wang, T.J.; Chang, P.Y.; Chen, C.Y.; Jian, Y.T.; Lin, Y.W. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells. Exp. Cell. Res. 2015, 334, 126-135.